Neurogen Announces Adipiplon As Nonproprietary Name for NG2-73
Neurogen Corporation (Nasdaq: NRGN), a drug discovery and development company, today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO), has approved the nonproprietary name “adipiplon” for Neurogen’s wholly-owned drug candidate for treatment of insomnia, NG2-73.
About adipiplon (formerly NG2-73)
To date adipiplon has been tested in over 600 subjects in eight clinical studies. Recent Phase 2b studies with primary chronic insomnia patients demonstrated doses that met primary endpoints for sleep induction and for sleep maintenance, with statistical and clinical significance. These doses evidenced no next-day residual effects. Also in these Phase 2b studies, adipiplon achieved statistical significance over placebo for improvement in patient-assessed sleep quality. This critical measure of patient satisfaction was also achieved in a Phase 2a study of adipiplon in transient insomnia–a model of insomnia conducted with healthy sleepers.
Adipiplon has a novel selectivity profile, different from currently marketed GABA insomnia drugs and from GABA drugs in development for treatment of insomnia. Adipiplon is a partial GABA agonist preferential for the alpha-3 subtype receptor, which is associated with the reduction of anxiety, as well as hypnotic, or sleep effects. In clinical studies to date, adipiplon has been shown to be safe and well tolerated.
About USAN
The purpose of the United States Adopted Names (USAN) Council is to serve the health professions in the United States by selecting simple, informative, and unique nonproprietary names for drugs by establishing logical nomenclature classifications based on pharmacological and/or chemical relationships.
The USAN Council (tri-sponsored by the American Medial Association (AMA), the United States Pharmacopeial Convention (USP), and the American Pharmacists Association (APhA), aims for global standardization and unification of drug nomenclature and related rules to ensure that drug information is communicated accurately and unambiguously, working closely with the International Nonproprietary Name (INN) Programme of the World Health Organization (WHO), and various national nomenclature groups.
About Neurogen
Neurogen Corporation is a drug discovery and development company focusing on small molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need, including insomnia, obesity, pain, Parkinson’s disease, and restless legs syndrome (RLS). Neurogen conducts its research and development independently and, when advantageous, collaborates with world-class pharmaceutical companies to access additional resources and expertise.
Neurogen Safe Harbor Statement
The information in this press release contains certain forward-looking statements, made pursuant to applicable securities laws, which involve risks and uncertainties as detailed from time to time in Neurogen’s SEC filings, including its most recent 10-K. Such forward-looking statements relate to activities, events or developments that Neurogen believes, expects or anticipates will occur in the future and include, but are not limited to, earnings estimates, statements that are not historical facts relating to Neurogen’s future financial performance, its growth and business expansion, its financing plans, the timing and occurrence of anticipated clinical trials, and potential collaborations or extensions of existing collaborations. These statements are based on certain assumptions made by Neurogen based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including, but not limited to, risks associated with the inherent uncertainty of drug research and development, difficulties or delays in development, testing, regulatory approval, production and marketing of any of Neurogen’s drug candidates, adverse side effects or inadequate therapeutic efficacy or pharmacokinetic properties of Neurogen’s drug candidates or other properties of drug candidates which could make them unattractive for commercialization, advancement of competitive products, dependence on corporate partners, Neurogen’s ability to retain key employees, sufficiency of cash to fund Neurogen’s planned operations and patent, product liability and third party reimbursement risks associated with the pharmaceutical industry. Although Neurogen believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. For such statements, Neurogen claims the protection of applicable laws. Future results may also differ from previously reported results. For example, positive results or safety and tolerability in one clinical study provides no assurance that this will be true in future studies. Forward-looking statements represent the judgment of Neurogen’s management as of the date of this release and Neurogen disclaims any intent and does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required under applicable law.